Biora Therapeutics undertakes Chapter 11 sale process to position business for future growth.

Learn more
Biora Therapeutics Home
Activate the mobile navigation

Publications

Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap™ targeted oral delivery platform and tofacitinib
#NaviCap Targeted Therapeutic Delivery
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
#NaviCap Targeted Therapeutic Delivery
Evaluation of the pharmacokinetics of GLP-1 receptor agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model: an update
#BioJet Oral Therapeutic Delivery
Evaluation of the pharmacokinetics of GLP-1 receptor agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model
#BioJet Oral Therapeutic Delivery
Potential effects of food on a novel Drug Delivery System (DDS) to deliver therapeutic compound into the colon
#NaviCap Targeted Therapeutic Delivery
Development of a novel Drug Delivery System (DDS) to deliver drugs directly to the colonic mucosa to improve efficacy and reduce systemic exposure for the treatment of ulcerative colitis (UC)
#NaviCap Targeted Therapeutic Delivery
A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis in fasted state
#NaviCap Targeted Therapeutic Delivery
A scintigraphic study to evaluate the safety, tolerability, and functionality of a Drug Delivery System (DDS) device in healthy volunteers in fasted state
#NaviCap Targeted Therapeutic Delivery
Pilot study to assess pharmacokinetic and pharmacodynamic markers following enema-dosing with adalimumab in patients with active ulcerative colitis
#NaviCap Targeted Therapeutic Delivery